Damora Therapeutics, Inc. (DMRA) is in Healthcare, Biotechnology, based in United States, listed on NasdaqCM. Market cap 1.27B USD. 52-week range 4.95 to 38.33 USD. Data as of 2026-10-09.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small ...